{"id":123,"date":"2013-06-21T18:35:55","date_gmt":"2013-06-21T09:35:55","guid":{"rendered":"http:\/\/urology.dept.med.gunma-u.ac.jp\/?p=123"},"modified":"2018-08-27T10:56:50","modified_gmt":"2018-08-27T01:56:50","slug":"2012%e5%b9%b4%e3%80%80%e6%a5%ad%e7%b8%be%e3%83%bb%e8%ab%96%e6%96%87","status":"publish","type":"post","link":"https:\/\/urology.dept.med.gunma-u.ac.jp\/?p=123","title":{"rendered":"2012\u5e74"},"content":{"rendered":"
    \n
  1. Arai S, Hasumi M, Shimizu N.\uff1a Long-term survival and onset of granulomatous pneumonia after lung metastasectomy in a patient with non-muscle-invasive bladder cancer..Int Urol Nephrol; 44(5):1383-7, 2012.<\/li>\n
  2. Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, Shibata Y and Suzuki K.\uff1a Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related induces in men with total PSA in the 2.0-10.0ng\/ml. World J Urol; Epub ahead of print,(31(2):305-311), 2012<\/li>\n
  3. Okamoto M, Ishikawa H, Ebara T, Kato H, Tamaki T, Akimoto T, Ito K, Miyakubo M, Yamamoto T, Suzuki K, Takahashi T and Nakano T.\uff1a Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: The relationship between dose-volume histogram parameters and the occurrence rate..Int J Radiat Oncol Biol Phys ; 82(2):e211-e217, 2012.<\/li>\n
  4. Kato H, Sekine Y, Nomura M, Nishii M, Matsui H, Hatori M, Ito K, Hirato J and Suzuki K.\uff1a Serous borderline tumor of the paratestis in a child.. BJUI.org; (web), 2012.<\/li>\n
  5. Nomura M, Ito K, Miyakubo M, Sekine Y, Tamura Y, Shimizu N, Aoki S and Suzuki K.\uff1a Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme.. Prostate Cancer and Prostatic Disease; 15(2):202-209, 2012.<\/li>\n
  6. Nishii M, Nomura M, Sekine Y, Koike H, Matsui H, Shibata Y, Ito K, Oyama T and Suzuki K.\uff1a Luteinizing horomone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: Implications for the effect of LH on the adrenal glands.. J Androl; 33(6):1233-1238, 2012.<\/li>\n
  7. Fukuma Y, Matsui H, Koike H, Sekine Y, Shechter I, Ohtake N, Nakata S, Ito K and Suzuki K.\uff1a Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer.. Prostate Cancer and Prostatic Disease; 15(4):339-345, 2012.<\/li>\n
  8. Magari T, Fukabori Y, Ogura H and Suzuki K.\uff1a Lower urinary tract symptoms of neurological origin in urological practice.. Clin Auton Res; 23(2):67-72(Epub:2012\u5e7410\u6708), 2012.<\/li>\n
  9. Magari T, Shibata Y, Arai S, Kashiwagi B and Suzuki K.\uff1a Influence of castration on bladder blood flow and function during the rapid phase of androgen deprivation.. Scand J Urol Nephrol; (Epub:2012\u5e7411\u6708), 2012.<\/li>\n
  10. Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K and Suzuki K.\uff1a Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.. Biochem Biophys Res Commun; 419(3):584-589, 2012.<\/li>\n
  11. Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K and Yamanaka H.\uff1a Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.; 15(1):75-86, 2012.<\/li>\n
  12. Sano R, Nakajima T, Takahashi K, Kubo R, Kominato Y, Tsukada J, Takeshita H, Yasuda T, Ito K, Maruhashi T, Yokohama A, Isa K, \uff1a Expression of ABO blood-group genes is dependent upon an erythroid cell-specific regulatory element that is deleted in persons with the Bm phenotype.. Blood; 119(22):5301-5310, 2012.<\/li>\n
  13. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u306e\u6700\u65b0\u60c5\u5831. \u764c\u3068\u5316\u5b66\u7642\u6cd5; 39(1):33-37, 2012.<\/li>\n
  14. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u764c\u3068PSA\u691c\u67fb. \u691c\u67fb\u3068\u6280\u8853; 40(2):111, 2012.<\/li>\n
  15. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u764c. \u4eca\u65e5\u306e\u8a3a\u7642\u306e\u305f\u3081\u306b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u5916\u6765\u8a3a\u76422012; pp.542-546, 2012.<\/li>\n
  16. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u764c\u306e\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3068\u5c02\u9580\u533b\u3078\u7d39\u4ecb\u3059\u308b\u30bf\u30a4\u30df\u30f3\u30b0\u306b\u3064\u3044\u3066\u6559\u3048\u3066\u304f\u3060\u3055\u3044. Geriat Med; 50(4):489-492, 2012.<\/li>\n
  17. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u304c\u3093PSA\u691c\u8a3a\uff1a\u6700\u65b0\u306e\u52d5\u5411\u3068\u65b9\u5411\u6027. \u4eba\u9593\u30c9\u30c3\u30af; 27(1):7-16, 2012.<\/li>\n
  18. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u304c\u3093\u306e\u30ea\u30b9\u30af\u5206\u985e\u306e\u6982\u8981\u3068\u30c6\u30fc\u30e9\u30fc\u30e1\u30a4\u30c9\u6cbb\u7642\u6226\u7565\u4e0a\u306e\u554f\u984c\u70b9. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(8):1713-1716, 2012.<\/li>\n
  19. \u4f0a\u85e4\u4e00\u4eba\uff1a \uff62\u5e73\u621023\u5e74\u5ea6\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\uff63\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u306e\u53cd\u5fdc\u3068\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u3067\u306e\u63a8\u5968\u5ea6. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(8):1751-1754, 2012.<\/li>\n
  20. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u304c\u3093\u306e\u65b0\u3057\u3044\u816b\u760d\u30de\u30fc\u30ab\u30fc. \u6ccc\u5c3f\u5668\u30b1\u30a2; 17(8):831-836, 2012.<\/li>\n
  21. \u4f0a\u85e4\u4e00\u4eba\uff1a \u65e5\u672c\u4eba\u306e\u524d\u7acb\u817a\u764c\u3068\u691c\u8a3a\u306e\u610f\u7fa9. \u30ab\u30ec\u30f3\u30c8\u30c6\u30e9\u30d4\u30fc; [\u5dfb\u53f7\u9801], 30(9):876-880.<\/li>\n
  22. \u4f0a\u85e4\u4e00\u4eba\uff1a \u524d\u7acb\u817a\u304c\u3093PSA\u691c\u8a3a\uff1a\u6700\u65b0\u306e\u7814\u7a76\u6210\u679c\u3068\u305d\u306e\u89e3\u91c8. \u65e5\u672c\u304c\u3093\u691c\u8a3a\u30fb\u8a3a\u65ad\u5b66\u4f1a\u8a8c; 20(2):139-143, 2012.<\/li>\n
  23. \u4f0a\u85e4\u4e00\u4eba\uff1a \uff62\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32010\u5e74\u5897\u88dc\u7248\uff63\u306e\u30dd\u30a4\u30f3\u30c8. \u6ccc\u5c3f\u5668\u30b1\u30a2; 17(12):1243-1245, 2012.<\/li>\n
  24. \u52a0\u85e4\u6625\u96c4\u3001\u67f4\u7530\u5eb7\u535a\u3001\u9234\u6728\u667a\u7f8e\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u9234\u6728\u548c\u6d69\uff1a \u30c8\u30ed\u30f3\u30dc\u30e2\u30c7\u30e5\u30ea\u30f3\u88fd\u5264\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u96c6\u5b66\u7684\u6cbb\u7642\u304c\u8457\u52b9\u3057\u305ff-TUL\u5f8c\u306e\u6557\u8840\u75c7\u6027\u30b7\u30e7\u30c3\u30af\u306e1\u4f8b. \u6ccc\u5c3f\u5668\u79d1\u7d00\u8981; 58(9):499-502, 2012.<\/li>\n
  25. \u718a\u5742\u6587\u6210\u3001\u52a0\u702c\u5609\u660e\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u6238\u585a\u771f\u5f13\u3001\u77f3\u79c0\u548c\u3001\u66f2\u3000\u53cb\u5f18\u3001\u72e9\u91ce\u3000\u81e8\u3001\u5c0f\u5009\u6cbb\u4e4b\u3001\u9ed2\u6fa4\u3000\u529f\u3001\u4f0a\u85e4\u4e00\u4eba\uff1a \u718a\u5742\u6587\u6210\u3001\u52a0\u702c\u5609\u660e\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u6238\u585a\u771f\u5f13\u3001\u77f3\u79c0\u548c\u3001\u66f2\u3000\u53cb\u5f18\u3001\u72e9\u91ce\u3000\u81e8\u3001\u5c0f\u5009\u6cbb\u4e4b\u3001\u9ed2\u6fa4\u3000\u529f\u3001\u4f0a\u85e4\u4e00\u4eba. \u4eba\u9593\u30c9\u30c3\u30af; 27(1):56-59, 2012.<\/li>\n
  26. \u718a\u5742\u6587\u6210\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u6751\u4e95\u3000\u52dd\u3001\u5cf6\u5d0e\u3000\u6df3\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5c71\u672c\u3000\u5de7\u3001\u8d64\u5009\u529f\u4e00\u90ce\uff1a \uff62\u5e73\u621023\u5e74\u5ea6\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\uff63\u4eba\u9593\u30c9\u30c3\u30af\u65bd\u8a2d\u306b\u304a\u3051\u308b\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u30a2\u30f3\u30b1\u30fc\u30c8\u96c6\u8a08\u5831\u544a\u2015\u5e73\u621022\u5e74\u5ea6\u8abf\u67fb\u2015. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(8):1741-1745, 2012.<\/li>\n
  27. \u718a\u5742\u6587\u6210\u3001\u52a0\u702c\u5609\u660e\u3001\u5c71\u4e2d\u82f1\u58fd\u3001\u5c0f\u5009\u6cbb\u4e4b\u3001\u66f2\u3000\u53cb\u5f18\u3001\u5bcc\u7530\u3000\u5149\u3001\u72e9\u91ce\u3000\u81e8\u3001\u9ed2\u6fa4\u3000\u529f\u3001\u5cf6\u7530\u548c\u5b50\u3001\u677e\u672c\u623f\u6c5f\u3001\u77f3\u4e95\u79c0\u548c\u3001\u4f0a\u85e4\u4e00\u4eba\uff1a \u4eba\u9593\u30c9\u30c3\u30af\u3067\u306e\u767a\u898b\u524d\u7acb\u817a\u304c\u3093\u75c7\u4f8b\u306b\u304a\u3051\u308bPSA\u751f\u9577\u66f2\u7dda\u306e\u691c\u8a0e. \u7fa4\u99ac\u533b\u5b66; 96:1-6, 2012.<\/li>\n
  28. \u9234\u6728\u548c\u6d69\uff1a \u9032\u884c\u6027\u30fb\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u30db\u30eb\u30e2\u30f3\u7642\u6cd5\u306e\u73fe\u72b6\u3068\u4eca\u5f8c\u306e\u5c55\u671b\u30fc\u524d\u7acb\u817a\u764c\u306e\u30a2\u30f3\u30c9\u30ed\u30b2\u30f3\u4f9d\u5b58\u6027\u306b\u95a2\u3059\u308b\u30d1\u30e9\u30c0\u30a4\u30e0\u30b7\u30d5\u30c8\u2015. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(\u7279\u5225):558-560, 2012.<\/li>\n
  29. \u9234\u6728\u548c\u6d69\u3001\u677e\u4e95\u3000\u535a\u3001\u9152\u4e95\u82f1\u6a39\uff1a \u75ab\u5b66. \u524d\u7acb\u817a\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32012\u5e74\u7248\u3000\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8; pp.10-18, 2012.<\/li>\n
  30. \u9234\u6728\u548c\u6d69\uff1a \u524d\u7acb\u817a\u764c\u53d6\u6271\u3044\u898f\u7d04\u30fb\u7b2c4\u7248\u30fc\u6539\u8a02\u306e\u30dd\u30a4\u30f3\u30c8\u3000\u5e8f\u6587. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(6):1259, 2012.<\/li>\n
  31. \u9234\u6728\u548c\u6d69\uff1a \u814e\u30fb\u6ccc\u5c3f\u5668\u75be\u60a3\uff1a\uff21\uff2c\uff30\u304a\u3088\u3073\uff30\uff33\uff21\u306e\u7570\u5e38\u9ad8\u5024\u3092\u304d\u305f\u3057\u305f64\u6b73\u306e\u7537\u6027\u30fc\u9032\u884c\u6027\u524d\u7acb\u817a\u764c. \u691c\u67fb\u3068\u6280\u8853; 40(10):1044-1050, 2012.<\/li>\n
  32. \u9234\u6728\u548c\u6d69\uff1a \u524d\u7acb\u817a\u764c\u2015\u53bb\u52e2\u62b5\u6297\u6027\u524d\u7acb\u817a\u764c\u306b\u5bfe\u3059\u308b\u30c9\u30bb\u30bf\u30ad\u30bb\u30eb\u306e\u5f79\u5272\uff1a\u52b9\u679c\u5224\u5b9a\u3068\u305d\u306e\u5f8c\u306e\u6cbb\u7642\u9078\u629e\u2015. \u764c\u3068\u5316\u5b66\u7642\u6cd5; 39(10):1467-1470, 2012.<\/li>\n
  33. \u9234\u6728\u548c\u6d69\uff1a \u304c\u3093\u6cbb\u7642\u306b\u3088\u308b\u9aa8\u91cf\u6e1b\u5c11\uff08\uff23\uff34\uff29\uff22\uff2c\uff09. \u304c\u3093\u9aa8\u8ee2\u79fb\u306e\u30d0\u30a4\u30aa\u30ed\u30b8\u30fc\u3068\u30de\u30cd\u30fc\u30b8\u30e1\u30f3\u30c8\u3000\u7c73\u7530\u4fca\u4e4b\u7de8; pp.200-206, 2012.<\/li>\n
  34. \u677e\u4e95\u3000\u535a\u3001\u5927\u7af9\u4f38\u660e\u3001\u6ff1\u91ce\u9054\u4e5f\u3001\u798f\u9593\u88d5\u4e8c\u3001\u4e2d\u7530\u8aa0\u53f8\u3001\u9234\u6728\u548c\u6d69\uff1a \u524d\u7acb\u817a\u764c\u306e\u907a\u4f1d\u7684\u7d20\u56e0\uff1a\u524d\u7acb\u817a\u764c\u8cac\u4efb\u907a\u4f1d\u5b50\u306e\u540c\u5b9a. \u65e5\u672c\u814e\u6ccc\u5c3f\u5668\u75be\u60a3\u4e88\u9632\u533b\u5b66\u7814\u7a76\u4f1a\u8a8c]; 20(1):38-40, 2012.<\/li>\n
  35. \u677e\u4e95\u3000\u535a\u3001\u5c0f\u6c60\u79c0\u548c\u3001\u68ee\u5ddd\u6cf0\u5982\u3001\u91ce\u6751\u660c\u53f2\u3001\u95a2\u6839\u82b3\u5cb3\u3001\u53e4\u8c37\u6d0b\u4ecb\u3001\u65b0\u7530\u8cb4\u58eb\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u67f4\u7530\u5eb7\u535a\u3001\u7fbd\u9ce5\u57fa\u660e\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u9234\u6728\u548c\u6d69\uff1a \u30b7\u30ed\u30c9\u30b7\u30f3\u306b\u3088\u308b\u6392\u5c3f\u969c\u5bb3\u306e\u6cbb\u7642\uff1aUrief Dose-up Study. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(1)49-53, 2012.<\/li>\n
  36. \u8d64\u5ea7\u82f1\u4e4b\u3001\u585a\u672c\u6cf0\u53f8\u3001\u9234\u6728\u548c\u6d69\u3001\u4e26\u6728\u5e79\u592b\u3001\u5927\u5712\u8aa0\u4e00\u90ce\u3001\u5185\u85e4\u8aa0\u4e8c\uff1a \u524d\u7acb\u817a\u764c\u306b\u304a\u3051\u308b\u6297\uff32\uff21\uff2e\uff2b\uff2c\u6297\u4f53\u30c7\u30ce\u30b9\u30de\u30d6\u306e\u6709\u7528\u6027. \u524d\u7acb\u817a\u764c\u306b\u304a\u3051\u308b\u6297\uff32\uff21\uff2e\uff2b\uff2c\u6297\u4f53\u30c7\u30ce\u30b9\u30de\u30d6\u306e\u6709\u7528\u6027; 39(2):207-212, 2012.<\/li>\n
  37. \u7530\u4e2d\u5553\u5e79\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u5bae\u4e45\u4fdd\u771f\u610f\u3001\u5cf6\u5d0e\u3000\u6df3\u3001\u5c71\u4e2d\u82f1\u58fd\uff1a \uff62\u5e73\u621023\u5e74\u5ea6\u524d\u7acb\u817a\u691c\u8a3a\u5354\u8b70\u4f1a\u904b\u55b6\u59d4\u54e1\u4f1a\u30fb\u524d\u7acb\u817a\u304c\u3093\u64b2\u6ec5\u63a8\u9032\u59d4\u54e1\u4f1a\u5408\u540c\u4f1a\u8b70\u3000\u8a18\u9332\uff63\u524d\u7acb\u817a\u304c\u3093\u691c\u8a3a\u7814\u7a76\u73ed\uff08\u7530\u4e2d\u73ed\uff09\u5e73\u621019\u5e74\u5ea6\u7d50\u679c\u5831\u544a. \u6ccc\u5c3f\u5668\u5916\u79d1; 25(8):1737-1740, 2012.<\/li>\n
  38. \u5e73\u5c3e\u4f73\u5f66\u3001\u9234\u6728\u548c\u6d69\u3001\u8d64\u5ea7\u82f1\u4e4b\u3001\u4f0a\u85e4\u4e00\u4eba\u3001\u8352\u4e95\u967d\u4e00\u3001\u5c0f\u5ddd\u3000\u4fee\u3001\u7b67\u3000\u5584\u884c\u3001\u85e4\u5143\u535a\u884c\u3001\u5bfa\u5730\u654f\u90ce\u3001\u9834\u5ddd\u3000\u664b\u3001\u5927\u5712\u8aa0\u4e00\u90ce\u3001\u4e09\u6728\u6052\u6cbb\u3001\u539f\u3000\u52f2\u3001\u4ed6\uff1a \u524d\u7acb\u817a\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32012\u5e74\u7248. \u524d\u7acb\u817a\u764c\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32012\u5e74\u7248\u3000\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8; , 2012.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Arai S, Hasumi M, Shimizu N.\uff1a Long-term survival and onset of granulomatous pneumonia after lung metastasectom […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-123","post","type-post","status-publish","format-standard","hentry","category-achievements"],"_links":{"self":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=123"}],"version-history":[{"count":5,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/123\/revisions"}],"predecessor-version":[{"id":1309,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=\/wp\/v2\/posts\/123\/revisions\/1309"}],"wp:attachment":[{"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urology.dept.med.gunma-u.ac.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}